An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Agilent and Visiopharm Expand Collaboration with Worldwide Distribution Agreement
Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
Agilent Technologies (NYSE: A) has signed a worldwide distribution agreement with Visiopharm to co-market AI-driven precision pathology software alongside Agilent's automated staining solutions. This collaboration, initially focused on Europe, marks Agilent's entry into the digital pathology market, which is projected to double in adoption by 2030. The COVID-19 pandemic has accelerated this trend as pathologists increasingly use remote reporting. The partnership aims to enhance diagnostic accuracy and workflow efficiency for pathologists, contributing to improved patient care.
Positive
Agilent enters the digital pathology market with a strategic partnership with Visiopharm.
The agreement allows Agilent to offer AI-driven precision pathology software, enhancing its product portfolio.
Digital pathology adoption is expected to double by 2030, indicating significant market growth potential.
The partnership has the potential to improve diagnostic accuracy and efficiency for pathologists.
Negative
None.
SANTA CLARA, Calif.--(BUSINESS WIRE)--
Agilent Technologies Inc. (NYSE: A) today announced the signing of a worldwide distribution agreement with Visiopharm, enabling Agilent to co-market Visiopharm’s portfolio of CE-IVD marked artificial intelligence (AI)-driven precision pathology software in addition to Agilent’s portfolio of automated pathology staining solutions. With an initial focus on Europe, this agreement marks Agilent's first entry into the growing digital pathology market and strengthens the relationship between the two companies by further expanding the scope of their long-term collaboration.
Digital pathology is experiencing rapid growth worldwide, with its adoption expected to double by the end of this decade. As the use of digital pathology increases, AI-driven pathology solutions are emerging as the new standard. These solutions can provide diagnostic decision support and productivity enhancements that enable pathologists to improve diagnostic accuracy and workload management.
This adoption has been accelerated by the COVID-19 pandemic, which has found pathologists increasingly reviewing cases remotely. In the United Kingdom, for example, pathologists have received guidance for remote reporting of digital pathology slides in times of exceptional service pressure and support in the adoption of technologies, such as digital pathology, that have the potential to aid in their assessment.
“This is an exciting next step in our partnership with Visiopharm,” said Lou Welebob, vice president and general manager of Agilent’s Pathology Division. “Being able to offer our customers digital pathology software alongside our range of automated staining solutions is a powerful combination that can support pathologists in their assessment and help improve patient care. We look forward to our continued collaboration with Visiopharm as we work together toward the fully digitalized pathology lab of the future.”
Michael Grunkin, CEO, Visiopharm said: “We're delighted to further expand our partnership with Agilent. With strong complementary solutions, we will be able to address recognized and currently unmet needs for both standardization and automation. This distribution agreement is a logical first step towards supporting those labs who share our joint vision of automated AI-driven precision pathology."
Prior to this announcement, Agilent and Visiopharm have collaborated to validate Visiopharm’s existing HER2 APP to include Agilent’s new HercepTest™ mAb pharmDx for Dako Omnis, both CE-IVD marked and available for sale in Europe. Released in October 2020, this product enables pathologists to use the Visiopharm HER2 APP for objective decision support in the assessment of HercepTest™ mAb pharmDx stained slides, saving valuable time for both pathologists and patients.
For in vitro diagnostic use in Europe.
HercepTest™ mAb pharmDx (Dako Omnis) (Code GE001):
The licensed antibody is created by Epitomics Inc. (an Abcam company), using Abcam’s proprietary rabbit monoclonal antibody technology covered under Patent No’s 5,675,063 and 7,402,409.
HercepTest™ and Herceptin® are trademarks owned by Genentech, Inc.
About Agilent Technologies
Agilent is a leader in life sciences, diagnostics, and applied chemical markets, delivering innovative technology solutions that provide trusted answers to researchers’ most challenging scientific questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.
What is Agilent Technologies' new partnership about?
Agilent Technologies has signed a distribution agreement with Visiopharm to co-market AI-driven precision pathology software and automated staining solutions.
How will the partnership affect Agilent Technologies' product offerings?
The partnership will enhance Agilent's product portfolio by integrating advanced digital pathology solutions with existing automated staining products.
What market is Agilent Technologies entering with this agreement?
Agilent is entering the digital pathology market, which is experiencing rapid growth and increasing adoption.
Why is digital pathology important for healthcare professionals?
Digital pathology improves diagnostic accuracy and productivity, enabling pathologists to manage their workloads more effectively.
What impact has the COVID-19 pandemic had on digital pathology?
The pandemic has accelerated the adoption of digital pathology as pathologists increasingly review cases remotely.
